- Record: found
- Abstract: not found
- Article: not found
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D Galsky ,
José Ángel Arranz Arija ,
Aristotelis Bamias ,
Ian D Davis ,
Maria De Santis ,
Eiji Kikuchi ,
Xavier Garcia-del-Muro ,
Ugo De Giorgi ,
Marina Mencinger ,
Kouji Izumi ,
Stefano Panni ,
Mahmut Gumus ,
Mustafa Özgüroğlu ,
Arash Rezazadeh Kalebasty ,
Se Hoon Park ,
Boris Alekseev ,
Fabio A Schutz ,
Jian-Ri Li ,
Dingwei Ye ,
Nicholas J Vogelzang ,
Sandrine Bernhard ,
Darren Tayama ,
Sanjeev Mariathasan ,
Almut Mecke ,
AnnChristine Thåström ,
Enrique Grande
May 2020
May 2020
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We
report the results of IMvigor130, a phase 3 trial that compared atezolizumab with
or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy
in first-line metastatic urothelial carcinoma.
Related collections
Author and article information
Comments
Comment on this article
scite_
0
0
0
0
Smart Citations0
0
0
0
Citing PublicationsSupportingMentioningContrasting
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.